Results 171 to 180 of about 222,862 (245)

Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. [PDF]

Sci Rep
Sezgin Y, Karhan O, Aldemir MN, Ürün M, Erçek BM, Urakcı Z, Arvas H, Tunç S, Erdem M, Yerlikaya H, İleri S, Aydın İ, Bicer A, Kömüroğlu AU, Majidova N, Gökçek S, Demir H, Yıldız S, Akbaş S, Özen E, Kahya BU, Sali M, Anık H, Aykut T, Araz M, Alkan A, Özçelik M, Sakin A, Aykan MB, Mehtıyev M, Demir B, Başer MN, Sönmez M, Gültürk İ, Avcı N, Urvay S, Arıcı MÖ, Kalender ME, Yıldırım M, Solmaz AA, Gürbüz M, Ergün Y.   +41 more
europepmc   +1 more source

Molecular subtyping and precision therapy for esophageal cancer

Interdisciplinary Medicine, EarlyView.
The molecular typing of esophageal cancer based on genome, transcriptome, proteome, and multi‐omics revealed various molecular features and provided potential targets for the precision therapy. Recent trials have shown that immunotherapy or molecular targeted therapy plus chemoradiotherapy can improve overall survival and progression‐free survival in ...
Guangkun Pei, Zhuoran Liang, Bianli Gu, Linlin Shi, Ze‐Xian Liu, Shegan Gao   +5 more
wiley   +1 more source

Acute Generalized Exanthematous Pustulosis With Negative Patch Test and Drug-Induced Lymphocyte Stimulation Test (DLST) Results: A Case Report. [PDF]

Cureus
Mima Y, Ohtsuka T.
europepmc   +1 more source

nab-paclitaxel/carboplatin induction in squamous NSCLC: Longitudinal quality of life while on chemotherapy [PDF]

, 2017
et al,, Morgensztern, Daniel
core   +1 more source

Nanomaterials for acute myeloid leukemia therapy: Current progress and future perspectives

Interdisciplinary Medicine, EarlyView.
Infographics of this review introducing the current treatment strategies, types of nanomaterials, and their advantages in AML treatment (Created with BioRender.com, a license purchased, accessed on March 26, 2024). Abstract Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by poor prognosis, high relapse rates ...
Jiarui Zhao, Jiaqi Cui, Lixuan Wang, Xinyi Shi, Jiayan Ding, Muhammad Farhan Sohail, Irshad Hussain, Qihui Liu, Fangfang Chen   +8 more
wiley   +1 more source

Exploring tubulin-paclitaxel binding modes through extensive molecular dynamics simulations. [PDF]

Sci Rep
Bozdaganyan M, Fedorov V, Kholina E, Kovalenko I, Gudimchuk N, Orekhov P.   +5 more
europepmc   +1 more source

Paclitaxel hypersensitivity

Cancer Research, Statistics, and Treatment, 2020
openaire   +2 more sources

Patient‐derived xenograft models in pan‐cancer: From bench to clinic

Interdisciplinary Medicine, EarlyView.
Abstract Patient‐derived xenograft (PDX) models provide a robust preclinical platform that preserves the genetic and phenotypic heterogeneity of patient tumors while mirroring their tumor genetic characteristics, which retain malignant cells and the tumor pathological structure, making them valuable for studying tumor progression and developing ...
Jiatong Li, Ao Gu, Nannan Tang, Gokhan Zengin, Meng‐Yao Li, Yingbin Liu   +5 more
wiley   +1 more source

Cost-effectiveness analysis of toripalimab combined with nab-paclitaxel as a first-line treatment for advanced TNBC in the US. [PDF]

PLoS One
Chen P, Qiao D, Xiao L, Deng G, Yang Q, Tian R.   +5 more
europepmc   +1 more source

Phase I/II Trial of Perioperative Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Junction Cancer

Journal of Surgical Oncology, EarlyView.
ABSTRACT Background and Objectives Standard treatment of patients with stage II/III esophageal or gastroesophageal junction (E/GEJ) cancer involves neoadjuvant chemoradiation (nCRT), resection, and immunotherapy. Our trial evaluated the addition of perioperative avelumab to standard treatments.
Nataliya V. Uboha, Mustafa M. Basree, Jens C. Eickhoff, Dustin A. Deming, Kristina Matkowskyj, James Maloney, Daniel McCarthy, Malcolm DeCamp, Noelle LoConte, Philip B. Emmerich, Sean Kraus, Monica A. Patel, Jeremy D. Kratz, Sam J. Lubner, Newton Hurst, Michael F. Bassetti   +15 more
wiley   +1 more source